Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City. - Palamar JJ; Rutherford C; Le A; Keyes KM. (2023)

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study. - Cavarra M; Mason NL; Kuypers KPC; Bonnelle V; Smith WJ; Feilding A; Kryskow P; Ramaekers JG. (2023)

A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder. - Escamilla R; González-Trujano ME; González Mariscal JM; Torres-Valencia JM; Guzmán-González H; Vega JL; Loizaga-Velder A. (2023)

Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy? - Crowe M; Manuel J; Carlyle D; Lacey C. (2023)

Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study. - Gramling R; Bennett E; Curtis K; Richards W; Rizzo DM; Arnoldy F; Hegg L; Porter J; Honstein H; Pratt S; Tarbi E; Reblin M; et al. (2023)

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report - Rebecchi K. (PsyArXiv, 2023)

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report (PsyArXiv, 2023)

A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics - Usona Institute (ClinicalTrials.gov, 2023)

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells. - Robinson GI; Li D; Wang B; Zahoruiko Y; Gerasymchuk M; Hudson D; Kovalchuk O; Kovalchuk I. (2023)

Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy. - Thase ME. (2023)

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. - Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R. (2023)

Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use. - Jones G; Herrmann F; Wang E. (2023)

Emerging Perspectives in Addiction Psychiatry. - Jordan A. (2023)

Substance use, harm reduction attitudes and behaviors among attendees of nature rave parties in Israel. - Bonny-Noach H; Shapira B; Baumol P; Tadmor N; Rosca P; Shoshan S; Harel-Fisch Y; Caduri A. (2023)

"But the reality is it's happening": A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy. - Downey AE; Boyd M; Chaphekar AV; Woolley J; Raymond-Flesch M. (2023)

Psilocybin-assisted psychotherapy for cancer-related anxiety and depression. - Yaniv D; Ramondetta LM; Cohen L; Amit M. (2023)

A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression. - Pilozzi A; Foster S; Mischoulon D; Fava M; Huang X (International journal of molecular sciences, 2023)

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. - Perez N; Langlest F; Mallet L; De Pieri M; Sentissi O; Thorens G; Seragnoli F; Zullino D; Kirschner M; Kaiser S; Solmi M; Sabé M. (2023)

The Potential of Psychedelics for the Treatment of Episodic Migraine. - Schindler EAD. (2023)

Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia. - Mamat R; Rashid RA; Shin SM; Ibrahim B; Wahab S; Ahmad A. (2023)

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice. - Jones NT; Zahid Z; Grady SM; Sultan ZW; Zheng Z; Razidlo J; Banks MI; Wenthur CJ. (2023)

Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022. - Jing X; Hoeh NR; Menkes DB. (2023)

Psilocybin for the treatment of anorexia nervosa. - Majić T; Ehrlich S. (2023)

Psychedelic drugs in the treatment of psychiatric disorders. - Ibrahim IB; Videbech P; Straszek SPV. (2023)

On the mushrooming reports of "quiet quitting": Employees' lifetime psilocybin use predicts their overtime hours worked. - Korman BA. (2023)

The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study - Brain; Cognition Discovery Foundation (ClinicalTrials.gov, 2023)

“Why would you open someone’s brain up?” Lived experience insights inform a psilocybin-assisted psychotherapy treatment manual for body image disturbance - Finkelstein C; Soha O; Roy A; Phillipou A; Rossell S. (Research Square, 2023)

An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients. - The Roots to Thrive Society for Psychedelic Therapy (ClinicalTrials.gov, 2023)

Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. - Husain MI; Blumberger DM; Castle DJ; Ledwos N; Fellows E; Jones BDM; Ortiz A; Kloiber S; Wang W; Rosenblat JD; Mulsant BH. (2023)

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. - Peck SK; Shao S; Gruen T; Yang K; Babakanian A; Trim J; Finn DM; Kaye WH. (2023)

Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters. - Jahanabadi S; Amiri S; Karkeh-Abadi M; Razmi A. (2023)

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. - Simonsson O; Carlbring P; Carhart-Harris R; Davis AK; Nutt DJ; Griffiths RR; Erritzoe D; Goldberg SB. (2023)

Distinctive Molecular and Metabolic Profiles of Chemically Synthesized Psilocybin and Psychedelic Mushroom Extract - Shahar O; Botvinnik A; Shwartz A; Lerer E; Buko A; Hamid E; Kahn D; Guralnick M; Blakolmer K; Wolf G; Lerer L; Lerer B; et al. (Research Square, 2023)

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression - Goodwin G; Marwood L; Mistry S; Nowakowska A; Simmons H; Tsai J; Williams S; Young M; Malievskaia E. (2023)

A proof-of concept randomized controlled trial to show that the antidepressant effect of psilocybin does not require a psychedelic experience: study protocol - Husain M; Blumberger D; Castle D; Kloiber S; Ortiz A; Rosenblat J; Mulsant B. (2023)

Psychedelics for depression: from neurobiology to treatment - Kuypers K. (2023)

Knocking on the Doors of Perception: the role of psilocybin in substance use disorder treatment - Sousa R; Costa L; Brás J; Vaz R; Martins J; Abreu J; Almeida E; Castro N; Andrade R; Cunha N. (2023)

The therapeutic potential of psilocybin in depression resistant to psychotropic drugs - Ramírez González J; Fernández Márquez I; Ferreiro González S; Ruíz E. (2023)

A systematic review to assess the use of psilocybin in the treatment of headaches - Bhanot S; Lin M; Bains S; Monroe A; Tsang V. (2023)

Systematic Review on the Mechanisms of Action of Psilocybin in the Treatment of Depression - Lin M; Lee H; Tsang V; Chai B; Howard A; Uy C; Elefante J. (2023)

Psilocybin as an antidepressant strategy - a review of safety aspects - Zeiss R. (2023)

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM. - Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D. (2023)

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions (PsyArXiv, 2023)

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions - Brennan B; Kelman A; Belser AB. (PsyArXiv, 2023)

Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour - Nkadimeng SM; Hay L; Steinmann CM; Eloff JN. (Research Square, 2023)

Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation. - Moujaes F; Rieser NM; Phillips C; de Matos NMP; Brügger M; Dürler P; Smigielski L; Stämpfli P; Seifritz E; Vollenweider FX; Anticevic A; Preller KH. (2023)

Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences. - Davis AK; Timmermann C; Ortiz Bernal AM; Lancelotta R; Nayak S; Sepeda ND; Nikolaidis A; Griffiths RR. (2023)

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. - Goodwin GM; Croal M; Feifel D; Kelly JR; Marwood L; Mistry S; O'Keane V; Peck SK; Simmons H; Sisa C; Stansfield SC; Tsai J; et al. (2023)

Must Psilocybin Always "Assist Psychotherapy"? - Goodwin GM; Malievskaia E; Fonzo GA; Nemeroff CB. (2023)

Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics. - Nogrady B. (2023)

Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study. - Więckiewicz G; Stokłosa I; Stokłosa M; Więckiewicz W; Gorczyca P; Gondek TM. (2023)

Psychedelic Experiences: Phenomenology, Therapeutic Potentials and Explanatory Models - Chernoff T; Kliger B; Venturini DH. (2023)

Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice - Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maede K; González-Maeso J; Kitagaki S; et al. (Research Square, 2023)

Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin - Tetem J; Fischmann T; Möller TJ. (PsyArXiv, 2023)

Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD) - Cybin Therapeutics Inc. (ClinicalTrials.gov, 2023)

Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin (PsyArXiv, 2023)

Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. - Hovmand OR; Poulsen ED; Arnfred S; Storebø OJ. (2023)

Navigating the chaos of psychedelic fMRI brain-entropy via multi-metric evaluations of acute psilocybin effects - McCulloch DE; Olsen AS; Ozenne B; Stenbaek DS; Armand S; Madsen MK; Knudsen GM; Fisher PM. (medRxiv, 2023)

Psilocybin's effects on cognition and creativity: A scoping review. - Bonnieux JN; VanderZwaag B; Premji Z; Garcia-Romeu A; Garcia-Barrera MA. (2023)

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. - Haridy R. (2023)

Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. - McIntyre RS. (2023)

Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents. - McIntyre RS. (2023)

Adapting psychedelic medicine for headache and chronic pain disorders. - Schindler EAD; Hendricks PS. (2023)

Assessing potential of psilocybin for depressive disorders. - Kozak Z; Johnson MW; Aaronson ST. (2023)

Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report. - Lawrence DW. (2023)

Alterations to self consciousness during mindfulness meditation and Flotation REST a comparative study - Gwyther M; Aspell JE. (PsyArXiv, 2023)

Alterations to self consciousness during mindfulness meditation and Flotation REST a comparative study (PsyArXiv, 2023)

Classical psychedelics in psychiatry - renaissance of interest and therapeutic perspectives. - Jachimowski A; Kucia K. (2023)

Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. - Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC. (2023)

Clinical specificity profile for novel rapid acting antidepressant drugs. - Scala M; Fanelli G; De Ronchi D; Serretti A; Fabbri C. (2023)

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder - Halucenex Life Sciences Inc. (ClinicalTrials.gov, 2023)

Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective. - De La Haye W; Walcott G; Eaton J; Beckford J; Greene J. (2023)

Psilocybin's Potential Mechanisms in the Treatment of Depression: A Systematic Review. - Lee HJ; Tsang VW; Chai BS; Lin MC; Howard A; Uy C; Elefante JO. (2023)

Psilocybin: The most effective moral bio-enhancer? - Rakić V. (2023)

Psilocybin decelerates cellular senescence - Hecker L; kato k; Kleinhenz JMK; Shin Y; Papageorgiou J; Zarrabi A. (Research Square, 2023)

Psychedelics, Meaningfulness, and the "Proper Scope" of Medicine: Continuing the Conversation. - Cheung K; Patch K; Earp BD; Yaden DB. (2023)

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review. - Zhornitsky S; Oliva HNP; Jayne LA; Allsop ASA; Kaye AP; Potenza MN; Angarita GA. (2023)

Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. - Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; et al. (2023)

Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats. - Tylš F; Vejmola Č; Koudelka V; Piorecká V; Kadeřábek L; Bochin M; Novák T; Kuchař M; Bendová Z; Brunovský M; Horáček J; Pálení Ček T. (2023)

Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data. - Bienemann B; Barbosa AR; Cruz LVMD; Multedo M; Mograbi D. (2023)

Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms. - Calder A; Mock S; Friedli N; Pasi P; Hasler G. (2023)

"Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli". - Flower JE; Gibbons WJ; Adams AM; Wang X; Broude CN; Jones JA. (2023)

Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis. - Nikolič M; Viktorin V; Zach P; Tylš F; Dudysová D; Janků K; Kopřivová J; Kuchař M; Brunovský M; Horáček J; Páleníček T. (2023)

A case-study evaluation of the "Copenhagen Music Program" for psilocybin-assisted therapy. - Ratkovic G; Sosteric M; Sosteric T. (2023)

The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs. - Lake S; Lucas P. (2023)

In vivo mapping of pharmacologically induced functional reorganization onto the human brain's neurotransmitter landscape. - Luppi AI; Hansen JY; Adapa R; Carhart-Harris RL; Roseman L; Timmermann C; Golkowski D; Ranft A; Ilg R; Jordan D; Bonhomme V; Vanhaudenhuyse A; et al. (2023)

Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition. - Mallaroni P; Mason NL; Reckweg JT; Paci R; Ritscher S; Toennes SW; Theunissen EL; Kuypers KPC; Ramaekers JG. (2023)

HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. - Lewis BR; Garland EL; Byrne K; Durns T; Hendrick J; Beck A; Thielking P. (2023)

The treatment of abandonment anxiety with MDMA and LSD - Turkia M. (PsyArXiv, 2023)

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study - Nayak SM; White S; Hilbert S; Lowe MX; Jackson H; Griffiths RR; Garcia-Romeu A; Yaden DB. (PsyArXiv, 2023)

Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin - A retrospective case study - Turkia M. (PsyArXiv, 2023)

The treatment of abandonment anxiety with MDMA and LSD (PsyArXiv, 2023)

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study - Nayak SM; White SH; Hilbert S; Lowe MX; Jackson H; Griffiths RR; Garcia-Romeu A; Yaden DB. (PsyArXiv, 2023)

Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study (PsyArXiv, 2023)

Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin - A retrospective case study (PsyArXiv, 2023)

No trip needed for psychedelics to lift mood? - O'Grady C. (2023)

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. - Gukasyan N; Griffiths RR; Yaden DB; Antoine DG; Nayak SM. (2023)

Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021. - Keyes KM; Patrick ME. (2023)

Cardioprotective Potential of the Ethanol and Water Extracts of Four Psilocybin Mushrooms on Angiotensin II-Induced Hypertrophy and Oxidative Stress on H9C2 Cardiomyocytes - Nkadimeng SM; Steinmann CM; Eloff JN. (Preprints.org, 2023)

Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence. - Koning E; Brietzke E. (2023)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. - Moliner R; Girych M; Brunello CA; Kovaleva V; Biojone C; Enkavi G; Antenucci L; Kot EF; Goncharuk SA; Kaurinkoski K; Kuutti M; Fred SM; et al. (2023)

Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. - Agin-Liebes G; Nielson EM; Zingman M; Kim K; Haas A; Owens LT; Rogers U; Bogenschutz M. (2023)

The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of Consciousness - Schmidt TT; Costines C; Tagliazucchi E; Millière R; Garrido JM; Cuiule JI. (PsyArXiv, 2023)

Is Microdosing a Placebo? - Polito V; Liknaitzky P. (PsyArXiv, 2023)

The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of Consciousness (PsyArXiv, 2023)

Is Microdosing a Placebo? (PsyArXiv, 2023)

Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression - Wall MB; Demetriou L; Giribaldi B; Roseman L; Ertl N; Erritzoe D; Nutt DJ; Carhart-Harris RL. (medRxiv, 2023)

Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories. - Benvenuti F; Colombo D; Soverchia L; Cannella N; Domi E; Ciccocioppo R. (2023)

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. - McCrone P; Fisher H; Knight C; Harding R; Schlag AK; Nutt DJ; Neill JC. (2023)

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. - Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D. (2023)

Global species diversity and distribution of the psychedelic fungal genus Panaeolus - Strauss D; Ghosh S; Murray Z; Gryzenhout M. (2023)

Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review - Halman A; Kong G; Sarris J; Perkins D. (medRxiv, 2023)

Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder. - Agrawal M; Emanuel E; Richards B; Richards W; Roddy K; Thambi P. (2023)

The Perilous Policy of Oregon's Psilocybin Services. - Holoyda B. (2023)

Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress. - Gold ND; Podrebarac SK; White LA; Marini C; Simon NM; Mittelman MS; Ross S; Bogenschutz MP; Petridis PD (Psychedelic medicine (New Rochelle, N.Y.), 2023)

UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. - Rijsketic DR; Casey AB; Barbosa DAN; Zhang X; Hietamies TM; Ramirez-Ovalle G; Pomrenze MB; Halpern CH; Williams LM; Malenka RC; Heifets BD. (2023)

The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics. - Evens R; Schmidt ME; Majić T; Schmidt TT. (2023)

Letter to the editor on "Increased low-frequency brain responses to music after psilocybin therapy for depression". - Brown O. (2023)

Psychedelics: Threshold of a Therapeutic Revolution. - Heal DJ; Smith SL; Belouin SJ; Henningfield JE. (2023)

Bridging the translational neuroscience gap: Development of the ‘shiftability’ paradigm and an exemplar protocol to capture psilocybin-elicited ‘shift’ in neurobiological mechanisms in autism - Whelan TP; Daly E; Puts NA; Malievskaia E; Murphy DG; McAlonan GM. (medRxiv, 2023)

Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans - Combat Stress (ClinicalTrials.gov, 2023)

New Pharmacologic Approaches to the Treatment of Bipolar Depression. - Keramatian K; Chakrabarty T; DuBow A; Saraf G; Yatham LN. (2023)

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. - Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; et al. (2023)

Neurobiological Correlates of Psilocybin Response in Depression. - Qasim S; Zaheer Z; Jawad MY; Shad MU. (2023)

Acute psilocybin increased cortical activities in rats. - Liu J; Wang Y; Xia K; Wu J; Zheng D; Cai A; Yan H; Su R. (2023)

Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers - University of Wisconsin; Madison (ClinicalTrials.gov, 2023)

Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review. - Fonseka LN; Woo BK. (2023)

[Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application]. - Lasch A; Schweikert T; Dora E; Kolb T; Schurig HL; Walther A. (2023)

Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders - Raithatha SA; Hagel JM; Matinkhoo K; Yu L; Press D; Cook SG; Sharma G; D D; Jensen G; Lee JB; Cai C; Gallant J; et al. (bioRxiv, 2023)

The evolution and ecology of psilocybin in nature. - Meyer M; Slot J. (2023)

Global species diversity and distribution of the psychedelic fungal genus Panaeolus. - Strauss D; Ghosh S; Murray Z; Gryzenhout M. (2023)

Henri Michaux's program for the psychedelic humanities. - Davis O. (2023)

A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin - University of Wisconsin; Madison (ClinicalTrials.gov, 2023)

Exposure therapy under psilocybin for general anxiety disorder and claustrophobia - THORENS G; PENZENSTADLER l; FURTADO LCDC; SERAGNOLI F; ROTHEN S; MABILAIS C; ZULLINO D. (Research Square, 2023)

Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience - Singleton SP; Timmermann C; Luppi AI; Eckernäs E; Roseman L; Carhart-Harris RL; Kuceyeski A. (bioRxiv, 2023)

Empirically validated theoretical analysis of visual-spatial perception under change of nervous system arousal. - Purohit P; Dutta P; Roy PK. (2023)

Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders. - Kargbo RB. (2023)

Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. - Singh S; Botvinnik A; Shahar O; Wolf G; Yakobi C; Saban M; Salama A; Lotan A; Lerer B; Lifschytz T. (2023)

The down-scheduling of MDMA and psilocybin(e): Too fast and too soon. - Kisely S. (2023)

The Need for Psychiatric Treatment among Polish Users of Psychoactive Substances Is Increasing: This and Other Results from the Newest PolDrugs Survey. - Więckiewicz G; Marek J; Stokłosa I; Szafoni S; Pluta S; Smukowska K; Żebrowska G; Stokłosa M; Gorczyca P; Pudlo R. (2023)

Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis. - Bae S; Vaysblat M; Bae E; Dejanovic I; Pierce M. (2023)

Effects of Psilocybin in Anorexia Nervosa - Johns Hopkins University (ClinicalTrials.gov, 2023)

Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. - Davis AK; Levin AW; Nagib PB; Armstrong SB; Lancelotta RL. (2023)

Corrigendum to 'Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity': Neuroimage 2022 Oct 15;260:119434. - Gaddis A; Lidstone DE; Nebel MB; Griffiths RR; Mostofsky SH; Mejia AF; Barrett FS. (2023)

Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder? - Rossell SL; Meikle SE; Williams ML; Castle DJ. (2023)

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. - Zeifman RJ; Wagner AC; Monson CM; Carhart-Harris RL. (2023)

Unblinding and demand characteristics in the treatment of depression. - Goodwin GM; Croal M; Marwood L; Malievskaia E (Journal of affective disorders, 2023)

[Drugs in the Developmental Stage (Psychotropics)]. - Uchida H. (2023)

Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’ - McAlpine R; Blackburne G; Kamboj S. (PsyArXiv, 2023)

Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’ (PsyArXiv, 2023)

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. - Ching THW; Grazioplene R; Bohner C; Kichuk SA; DePalmer G; D'Amico E; Eilbott J; Jankovsky A; Burke M; Hokanson J; Martins B; Witherow C; et al. (2023)

A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. - Weiss B; Erritzoe D; Giribaldi B; Nutt DJ; Carhart-Harris RL. (2023)

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2023)

Increased low-frequency brain responses to music after psilocybin therapy for depression. - Wall MB; Lam C; Ertl N; Kaelen M; Roseman L; Nutt DJ; Carhart-Harris RL. (2023)

A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy - Bennett JN; Blough MD; Mitchell I; Galloway L; Bains R. (medRxiv, 2023)

High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin - Braun D; Rosenberg A; Haruvi R; Malamud D; Barbara R; Kawashima T. (bioRxiv, 2023)

Psilocybin in Palliative Care: An Update. - Whinkin E; Opalka M; Watters C; Jaffe A; Aggarwal S. (2023)

Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice. - Wang K; Sun Y; Nava B; Sampiere L; Jacobs RJ. (2023)

Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. - Effinger DP; Quadir SG; Ramage MC; Cone MG; Herman MA. (2023)

TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology. - Ort A; Smallridge JW; Sarasso S; Casarotto S; von Rotz R; Casanova A; Seifritz E; Preller KH; Tononi G; Vollenweider FX. (2023)

The Theoretical Description for Psilocin Electrochemical Determination over Cobalt Oxyhydroxide - Volodymyr Tkach; Kucher Mykhailo; Kushnir Marta; Ivanushko Yana; Akınay Yüksel; Karakoyun Necdet; Yagodynets Petro; Kormosh Zholt (Orbital: The Electronic Journal of Chemistry, 2023)

Use of Selective Alternative Therapies for Treatment of OCD. - Khan I; Jaura TA; Tukruna A; Arif A; Tebha SS; Nasir S; Mukherjee D; Masroor N; Yosufi A. (2023)

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. - Jefferson SJ; Gregg I; Dibbs M; Liao C; Wu H; Davoudian PA; Woodburn SC; Wehrle PH; Sprouse JS; Sherwood AM; Kaye AP; Pittenger C; et al. (2023)

The molecular basis of the antidepressant action of the magic mushroom extract, psilocin. - Hakami Zanjani AA; Nguyen TQT; Jacobsen L; Khandelia H. (2023)

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. - Zia FZ; Baumann MH; Belouin SJ; Dworkin RH; Ghauri MH; Hendricks PS; Henningfield JE; Lanier RK; Ross S; Berger A. (2023)

Psilocybin zeigt Wirkung bei Depression. - Julia Mertens L. (2023)

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. - Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB (Journal of affective disorders, 2023)

Liminal spaces, seasonal faces: Challenging drug market assumptions via an exploration of naturally occurring magic mushroom markets in rural Kent. - Simpson GHR; Chatwin C; van Hellemont E (The International journal on drug policy, 2023)

Systematic Review of Interventions for Demoralization in Patients With Cancer. - Wang Y; Sun H; Ji Q; Wei J; Zhu P. (2023)

Classic psychedelic use and current meditation practice. - Simonsson C; Chambers R; Hendricks PS; Goldberg SB; Osika W; Schlosser M; Ryde A; Christersson E; Simonsson O (Mindfulness, 2023)

Psychotherapy with Psilocybin for Depression: Systematic Review. - Dawood Hristova JJ; Pérez-Jover V. (2023)

The need for establishing best practices and gold standards in psychedelic medicine. - Feduccia A; Agin-Liebes G; Price CM; Grinsell N; Paradise S; Rabin DM. (2023)

Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. - Du Y; Li Y; Zhao X; Yao Y; Wang B; Zhang L; Wang G. (2023)

Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2023)

[Contribution of serotonin 5-HT2A receptor to antidepressant effect of serotonergic psychedelics]. - Ibi D. (2023)

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. - Schneier FR; Feusner J; Wheaton MG; Gomez GJ; Cornejo G; Naraindas AM; Hellerstein DJ. (2023)

Role of Psychedelics in Treatment-Resistant Depression. - Kamal S; Jha MK; Radhakrishnan R. (2023)

In silico characterization of the psilocybin biosynthesis pathway. - Irvine W; Tyler M; Delgoda R. (2023)

Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism. - Domanegg K; Sommer WH; Meinhardt MW. (2023)

Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. - Rosenblat JD; Leon-Carlyle M; Ali S; Husain MI; McIntyre RS. (2023)

The Unique Neural Signature of Your Trip: Functional Connectome Fingerprints of Subjective Psilocybin Experience - Tolle HM; Farah JC; Mallaroni P; Mason NL; Ramaekers JG; Amico E. (bioRxiv, 2023)

[Psychedelic Therapy with Psilocybin and Psychotherapy - Where do we Stand?] - Karow A. (2023)

Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study - Optimi Health Corporation (ClinicalTrials.gov, 2023)

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. - Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC. (2023)

Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. - Sharma R; Batchelor R; Sin J. (2023)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD - Ching THW; Grazioplene R; Pittenger C; Kelmendi B. (PsyArXiv, 2023)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD (PsyArXiv, 2023)

Trends in drug use among nightclub and festival attendees in New York City, 2017-2022. - Palamar JJ; Le A; Cleland CM; Keyes KM. (2023)

Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health. - Ryan RS; Copello A; Fox AP (BMC psychiatry, 2023)

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice. - Zanikov T; Gerasymchuk M; Ghasemi Gojani E; Robinson GI; Asghari S; Groves A; Haselhorst L; Nandakumar S; Stahl C; Cameron M; Li D; Rodriguez-Juarez R; et al. (2023)

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. - Brett J; Knock E; Korthuis PT; Liknaitzky P; Murnane KS; Nicholas CR; Patterson JC; Stauffer CS. (2023)

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder - New York State Psychiatric Institute (ClinicalTrials.gov, 2023)

A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression. - Hibicke M; Kramer HM; Nichols CD. (2023)

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice. - Aday JS; Skiles Z; Eaton N; Fredenburg L; Pleet M; Mantia J; Bradley ER; Fernandes-Osterhold G; Woolley JD. (2023)

Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. - Wulff AB; Nichols CD; Thompson SM. (2023)

Understanding psychedelic 'mystical experience'-A case example - Turkia M. (PsyArXiv, 2023)

Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study - Turkia M. (PsyArXiv, 2023)

Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study - Turkia M. (PsyArXiv, 2023)

Understanding psychedelic 'mystical experience'-A case example (PsyArXiv, 2023)